Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

PLoS One · 2014 · PMC3974707 · PMID 24699248

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

The effects of GSK263 on total GIP were variable and not significant, but there was a strong trend for sitagliptin to reduce GIP levels ( Figure 3A and 3B and Tables 6 and 7 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.